Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 2.

Journal Article

Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., Dela Serna, J., Dilhuydy, M. S., Opat, S., Owen, C. J., Samoylova, O., Kreuzer, K. A., Langerak, A. W., Ritgen, M., Stilgenbauer, S., Doehner, H., Asikanius, E., Humphrey, K., Wenger, M. K. and Hallek, M. (2014). Obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukaemia (CLL) and comorbidities: recently published results of the CLL11 trial. Br. J. Haematol., 165. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Goede, V., Fischer, K., Engelke, A., Schlag, R., Lepretre, S., Montero, L. F. C., Montillo, M., Fegan, C., Asikanius, E., Humphrey, K., Fingerle-Rowson, G. and Hallek, M. (2015). Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia, 29 (7). S. 1602 - 1606. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

This list was generated on Sun Apr 21 02:06:52 2024 CEST.